Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...
IEEE

Linear Recursive Non-Local Edge-Aware Filter

Abstract: It is challenging to extend the support region of state-of-the-art local edge-preserving filtering approaches to the entire input image on account of huge memory cost and heavy computational ...
IEEE

On Redundancy Reduction of Non-Recursive Second-Order Spectral-Null Codes

Abstract: The code design problem of non-recursive second-Order Spectral Null (2-OSN) codes is to convert balanced information words into 2-OSN words employing the minimum possible redundancy. Let k ...
Frontiers

Visual recursion without recursive language? a case study of a minimally verbal autistic child

The human faculty to generate an infinite set of structured expressions in language, present in most cultures and normal ontogeny, is the most substantial evidence of the human capacity for recursion.
marktechpost

Relaxed Recursive Transformers with Layer-wise Low-Rank Adaptation: Achieving High Performance and Reduced Computational Cost in Large Language Models

Large language models (LLMs) rely on deep learning architectures that capture complex linguistic relationships within layered structures. Primarily based on Transformer architectures, these models are ...
bernama

Recursion: Non-antibiotic Treatment For Recurrent C. diff Infection Enters Phase 2 Trial

KUALA LUMPUR, Oct 23 (Bernama) -- Recursion, a clinical stage TechBio company, announced the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral ...
BioSpace

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...